Current therapy option for necrotizing enterocolitis: Practicalities and challenge

Huihuan Wu; Kehang Guo; Zewei Zhuo; Ruijie Zeng; Yujun Luo; Qi Yang; Jingwei Li; Rui Jiang; Zena Huang; Weihong Sha; Hao Chen

doi:10.3389/fped.2022.954735

Current therapy option for necrotizing enterocolitis: Practicalities and challenge

Front Pediatr. 2022 Jul 28:10:954735. doi: 10.3389/fped.2022.954735. eCollection 2022.

Authors

Huihuan Wu^{1

2}, Kehang Guo^{1

2}, Zewei Zhuo^{1

3}, Ruijie Zeng^{1

4}, Yujun Luo¹, Qi Yang¹, Jingwei Li¹, Rui Jiang^{1

2}, Zena Huang⁵, Weihong Sha^{1

2}, Hao Chen^{1

2}

Affiliations

¹ Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
² School of Medicine, South China University of Technology, Guangzhou, China.
³ School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.
⁴ Shantou University Medical College, Shantou, China.
⁵ Department of General Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.

Abstract

Necrotizing enterocolitis (NEC) is one of the most prevalent neonatal gastrointestinal disorders. Despite ongoing breakthroughs in its treatment and prevention, the incidence and mortality associated with NEC remain high. New therapeutic approaches, such as breast milk composition administration, stem cell therapy, immunotherapy, and fecal microbiota transplantation (FMT) have recently evolved the prevention and the treatment of NEC. This study investigated the most recent advances in NEC therapeutic approaches and discussed their applicability to bring new insight to NEC treatment.

Keywords: breast milk composition; fecal microbiota transplantation; immunotherapy; necrotizing enterocolitis; stem cell.

Publication types

Review